announcement here read

OBJ Limited (ACN 056 482 636)
Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007
Phone: +61 9 9443 3011 Fax: +61 9 9443 3866 Email: [email protected]
Tuesday, March 1st 2005

FOR IMMEDIATE RELEASE

OBJ DEMONSTRATES FINE CONTROL OVER

DRUG DELIVERY RATES
==============================================

OBJ Limited (OBJ) is pleased to announce that its Dermaportation drug
delivery technology had successfully demonstrated the ability to provide a high
level of control over drug delivery rates in vitro .
In an independent research program, conducted the Western Australia
Biomedical Research Institute (WABRI), found that Dermaportation was able
to control the delivery rates of the drug caffeine through donated human skin,
across a range of delivery rates from t 0.6 µg/cm2 through to 19.2 µg/cm2.
The research program, which sought to define Dermaportation’s high resolution
control processes, showed that fine management control could be achieved
using OBJ’s electronic patch technology.
WABRI found that Dermaportation could either accelerate rates of drug delivery
by as much as 280% or decrease them to 36%.
The new findings will be presented at the annual conference of the Australian
Society of Cosmetic Chemists Brisbane on March 17th-20th.
The company believes that these promising results represent a significant step
forward in drug delivery technology.


Background to the Announcement
OBJ Limited is a drug delivery company, developing electronic “drug
patch” technologies that allow drugs, therapeutic agents and cosmetic
compounds to be delivered more effectively and more efficiently throughthe-
skin.
OBJ’s technology works by temporarily changing the skin’s barrier effect.
As this does not involve a change to the target drug or compound, new
and effective delivery strategies can be created without the necessity for
the drug to undergo costly re-registration. This technology provides
pharmaceutical companies with a market friendly, cost effective and
safe route of administration for many existing and newly created drugs
and compounds.
The company has previously announced a 600% increase in the rate of
delivery of the drug caffeine and a 70% reduction in the through-the-skin
delivery times for the anaesthetic drugs lignocaine and prilocaine
hydrochloride.
Independence of Results
OBJ contracts its drug and technology testing programs to independent
and respected organisations, such as Western Australian Biomedical
Research Institute or WABRI and Universities.
WABRI is a government owned and funded drug development and
testing facility operated by Curtin University. The high level of
independence and international accreditation means that the results by
OBJ can be published and presented at major medical and scientific
conferences and forums.

For more information:
Jeffrey Edwards
Phone: +61 8 944 33011
Mobile: 041 791 2211
E-mail: [email protected]